Stock Taper
SCREENER COMPARE ANY 2 STOCKS
KPTI
KARYOPHARM THERAPEUTICS INC.
NASDAQ
$1.87
▼ DOWN 3.61% (-0.07)

KEY STATISTICS

Market Cap$42.38 M
52w High$10.99
52w Low$1.79
Dividend Yield—
Frequency—
P/E-0.14
Volume823.17K
Shares Out.22.66M

COMPANY

LEADERSHIP

Richard A. Paulson
CHIEF EXECUTIVE
Richard A. Paulson

COMPENSATION 2026

Salary$770,000
Stock Awards$838,996
Incentive Plan Pay$350,350
All Other Comp.$19,912
Total$2,320,902

ABOUT

SECTOR
Healthcare
WENT PUBLIC
November 6, 2013
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
228

PRICE TARGET

Target High$28.00
Target Low$3.00
Target Median$16.00
Target Consensus$13.20

UPCOMING EARNINGS

DateNov 2, 2026
DayMonday
Rev. Est.$33.54M
NOV
2
MON

SPLIT RECORD

DATETYPERATIO
2025-02-26Reverse1:15

PRICE

$1.87 ▼ DOWN 3.61% (−$0.07)
OVERLAYS
$1.85$1.90$1.95$2.009:31 AM10:36 AM11:40 AM12:45 PM1:50 PM2:54 PM3:59 PM1.87

About Karyopharm Therapeutics Inc.

https://www.karyopharm.com ↗

Karyopharm Therapeutics develops and commercializes SINE compounds targeting nuclear export, with lead drug XPOVIO for multiple myeloma and lymphoma, licensed in Europe and Latin America, focusing on cancer treatments.

INDUSTRY

Biotechnology

A PRODUCT KARYOPHARM THERAPEUTICS INC. IS KNOWN FOR

XPOVIO® (selinexor)
XPOVIO® (selinexor)

XPOVIO® is an oral cancer treatment approved for multiple myeloma and relapsed/refractory diffuse large B-cell lymphoma, serving as Karyopharm's flagship product focused on targeting cancer's fundamental mechanisms.

COMPETITORS

COMPETITOR
AMGN COMPARE
BMY COMPARE
JNJ COMPARE
TAK COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
License and Service$11.14M $1.35M ▼$1.83M ▲$1.9M ▲
Health Care Other$200K $259K ▲$3.58M ▲$77K ▼

Revenue by Geography

MapREGIONFY2020
CANADA$5M

ETFS HOLDING THIS STOCK

ETFS HOLDING
56
LISTED HERE
12
RANKED BY POSITION SIZE
VTS.AX
0.00% · 677.7K
IWM
0.00% · 483.9K
FESM
0.01% · 173.7K
OMFS
0.02% · 35.9K
GSSC
0.01% · 34.0K
XRS2.DE
0.00% · 18.2K
ZPRR.DE
0.00% · 11.5K
RSSL
0.00% · 9.4K
PQ
PQSG
0.20% · 2.8K
URTY
0.00% · 811
FLQS
0.00% · 570
RESM
0.00% · 39

INSTITUTIONAL OWNERSHIP

SHARES OWNED
85.70%
HOLDERS
130
TOP 12 OF 130 · RANKED BY POSITION SIZE
Blackrock Inc.
4.2M sh · $3.62M
Delphi Management Partners Viii, L.L.C.
2.3M sh · $13.17M
Commodore Capital LP
1.9M sh · $10.86M
Ra Capital Management, L.P.
1.9M sh · $10.68M
Adage Capital Partners Gp, L.L.C.
1.8M sh · $10.06M
T. Rowe Price Investment Management, Inc.
1.5M sh · $8.59M
Blackrock Fund Advisors
1.4M sh · $12.94M
Goldman Sachs Group Inc
947.6K sh · $5.28M
Opaleye Management Inc.
930.0K sh · $6.84M
Catalio Capital Management, LP
897.7K sh · $5M
Affinity Asset Advisors, LLC
889.6K sh · $6.55M
Ikarian Capital, LLC
733.4K sh · $4.09M

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
OFFICER: EVP, CHIEF DEVELOPMENT OFFICER
Poulton Stuart
Sale · 189 shares
2026-07-28
★
DIRECTOR
Greene Barry E
Purchase · 15.5K shares
2026-05-21
★
DIRECTOR
PAKIANATHAN DEEPIKA
Purchase · 15.5K shares
2026-05-21
★
DIRECTOR
Schor Chen
Purchase · 15.5K shares
2026-05-21

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 2
NEUTRAL 1
OVERWEIGHT 1
4 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. NEUTRAL Piper Sandler OVERWEIGHT Baird OUTPERFORM RBC Capital OUTPERFORM

SECTORS PEERS

PEERPRICE
XFOR$4.04COMPARE
TELO$1.14COMPARE
INMB$2.33COMPARE
ALGS$6.91COMPARE
BRNS$0.75COMPARE
SNTI$0.38COMPARE
MDCX$0.26COMPARE